Drugs / BGC20-0134
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01037907 | Nov 2009 → Dec 2011 | relapsing-remitting multiple sclerosis | Boston Scientific Corporation | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGC20-0134 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01037907 ↗ |
| Known as | Pleneva TM | “A Placebo-controlled Phase IIa Study of Orally Administered BGC20-0134/Pleneva TM (Structured Lipid) in Patients With RRMS” NCT01037907 ↗ |
| Route | Oral | “Orally Administered BGC20-0134” NCT01037907 ↗ |